Gregory A. Otterson MD

Oncology•Columbus, OH

Professor, Internal Medicine, Ohio State University College of Medicine

Join to View Full Profile

460 W 10th AveColumbus, OH 43210
Phone+1 614-293-6529
Fax+1 614-293-9469

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Rush University Medical CenterResidency, Internal Medicine, 1986 - 1989
Georgetown University School of MedicineClass of 1986

Certifications & Licensure

OH State Medical License 1998 - 2024
MD State Medical License 1989 - 1999
IL State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACP) American College of Physicians, 2002
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Capecitabine in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Nov 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Solid Tumors Start of enrollment: 2001 Jan 01
Unknown status
Phase 1
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 1
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2008 Aug 14
Completed
Phase 2
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Start of enrollment: 2012 Mar 16
Completed
Phase 2
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients.
Anet Greib, Songzhu Zhao, Michelle Ploch, Jonathan Henricks, Robert Easterling
Oncoimmunology. 2025-12-01
2 citations
A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer.
Terence M Williams, Eric Miller, Meng Welliver, Jeremy Brownstein, Gregory Otterson
International Journal of Radiation Oncology, Biology, Physics. 2024-11-01
CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment.
Adam Khorasanchi, Songzhu Zhao, Lai Wei, Mingjia Li, Kevin Ho
Journal of the National Comprehensive Cancer Network. 2024-04-05

Journal Articles

Identifying Patterns of Care for Elderly Patients with Non-Surgically Treated Stage III Non-Small Cell Lung Cancer: An Analysis of the National Cancer Database
Kai He, Terence M Williams, John C Grecula, Eric D Miller, Erin M Bertino, David P Carbone, Peter G Shields, Jose G Bazan, Karl E Haglund, Gregory A Otterson, BioMed Central

Press Mentions

Targeted Therapy of Lung Cancer – Lung Cancer Targeted TherapyOctober 28th, 2015

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow